RE: Another failed pump ...23 May 2024 13:52
This is why you make people leave this forum! You encourage the likes of Stu to pipe up also spreading half truths, lies and misinformation.
As I spelt out in my message pharma is at an all-time low in terms of investor sentiment and 'new money' arriving due to 'risk'. Risk of loss. Risk of failure. The pandemic, war, fiscal cycles, inflation, increasing interest rates (making saving more attractive) all contribute to very little new money hitting high risk sectors, like pharma.
Specifically to HEMO, everyone knows funding is of primary important to all junior pharmas. Those astute out there know its been a very difficult back drop to raise any funds at all in the last couple of years so on one hand HEMO has done excellent raising what it has. Which could indeed be taken as a very positive sign that things are expected at HEMO by those with money.
Many companies simply have had no backing, been unable to raise finances and have gone bust. HEMO will need more funds but are in a stronger position now going clinical in terms of accessing what they need when they need it. IMO.
So whilst junior pharma has been off the radar for many investors in general for a good 3 years+ due to the inherent risk. Exceeding most risk appeties. However, those who are aware of HEMO could still be waiting for more progress on trials. It's understandable. The more positive information out there regards progress via RNS then the less risk there is. So it's a trade off. That old cliche risk v reward.
Buy now for higher risk and higher rewards (so cheap so huge upside) but with more risk of failure than say in 3 months when trials have commenced. Or further reduced risk in 6 months when the first results have come back positive. Even less risk after securing further funding though I dont think we need anything til nearer the year end.
Everyone has a different appetite for risk. And each level of risk appetite prefers the risk/reward trade off at different stages of the HEMO CAR T timeline through to proof of concept.
Adventurous investor buys now in the hope of multibags while the cautious investor waits for positive results on the trials in acceptable for say a 50% target return. (I have bought more down here Stu, thanks for asking).
Mr India is tedious. I KNOW you have been in and out of HEMO so stop lying.
Put it like this Mr India - why didn't everyone buy TESLA when it was cheap, or Apple, or IBM? Lack of research, risk appetite not quite there, lack of understanding of the company and its product(s) and area of application. Take your pick.
The people on here who have bought now are buying when the picture is hazy in the distance. Some want the picture to clear as they got closer to the end game but for that, you pay more.
Good luck to you both.
Sign In
Follow the stocks
